Viridian Therapeutics’ stock up 35% after Phase III TED data release
Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.
06 May 2026
06 May 2026
Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.